French health and beauty company Sanofi has said that financial results for 1994 were satisfactory and in line with expectations. For the year, sales amounted to 26.1 billion French francs ($5 billion), ahead of 1993 sales by 11.1%.
Sales of human health care products grew 17.6% to 14.8 billion francs. Within this sector, pharmaceutical sales were strong in northern Europe. Also, there were significant increases in Asia, and sales in North and South America, which were consolidated last year, were said to be satisfactory.
The group's diagnostics business attributed growth in the sector to the continued launch of its Access automated immunodiagnostic system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze